Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2026)

Amneal Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 19.62% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 519.0% year-over-year to 19.62%; the TTM figure through Mar 2026 stood at 14.3% (up 156.0% YoY), while the FY2025 annual figure was 13.05%, up 413.0% from the prior year.
• EBITDA Margin was 19.62% for Q1 2026 at Amneal Pharmaceuticals, up from 13.76% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 803.62% in Q1 2022 to a low of 35.51% in Q2 2022.
• Historically, EBITDA Margin has averaged 53.83% across 5 years, with a median of 12.2% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 79431 bps in 2022, then tumbled 79744 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 2.28% in 2022, then jumped by 201 bps to 2.3% in 2023, then soared by 351 bps to 10.38% in 2024, then jumped by 33 bps to 13.76% in 2025, then jumped by 43 bps to 19.62% in 2026.
• The last three EBITDA Margin figures came in at 19.62% (Q1 2026), 13.76% (Q4 2025), and 8.97% (Q3 2025), per Business Quant data.